s_150203_4b
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- e1_e2
- E2
- umap1_2d
- -6.961237466
- umap2_2d
- 0.558082424
- umap1_3d
- 0.467237658
- umap2_3d
- 3.323010188
- umap3_3d
- 1.167422469
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.320
- E2F_TARGETS+0.310
- G2M_CHECKPOINT+0.250
- SPERMATOGENESIS+0.240
- ANGIOGENESIS+0.210
- PANCREAS_BETA_CELLS+0.190
- NOTCH_SIGNALING+0.170
- KRAS_SIGNALING_DN+0.150
- DNA_REPAIR+0.140
- HEDGEHOG_SIGNALING+0.130
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.410
- INTERFERON_ALPHA_RESPONSE-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ANDROGEN_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- APOPTOSIS-0.310
- ALLOGRAFT_REJECTION-0.290
- COMPLEMENT-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.874 |
| 2 | BS_44A3ES23 | medulloblastoma | — | 0.872 |
| 3 | TCGA-XF-AAMG-01A-11R-A42T-07 | — | — | 0.841 |
| 4 | BS_PQVTB6BB | high-grade glioma | — | 0.837 |
| 5 | SRR6013547 | — | cohortMD1 | 0.825 |
| 6 | BS_P39SQPTS | Embryonal tumors | — | 0.822 |
| 7 | TCGA-NK-A5D1-01A-11R-A26W-07 | — | cohortMD1 | 0.815 |
| 8 | BS_JT82QGXF | medulloblastoma | — | 0.812 |
| 9 | SRR2016964 | — | — | 0.812 |
| 10 | SAMN03290896 | — | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |